The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
Open accessAbstract
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. Methods This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1–18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10−4 cells) received an allogenic stem-cell transplant. Standard-risk and intermediate-risk patients with postinduction low minimal residual disease (<10−4 cells) continued chemotherapy. The primary outcome was progression-free survival and the method of analysis was intention-to-treat. Randomisation was stopped in December, 2007 because of differences in progression-free and overall survival between the two groups. This trial is registered, reference number ISCRTN45724312. Findings Of 239 registered patients, 216 were randomly assigned to either idarubicin (109 analysed) or mitoxantrone (103 analysed). Estimated 3-year progression-free survival was 35·9% (95% CI 25·9–45·9) in the idarubicin group versus 64·6% (54·2–73·2) in the mitoxantrone group (p=0·0004), and 3-year overall survival was 45·2% (34·5–55·3) versus 69·0% (58·5–77·3; p=0·004). Differences in progression-free survival between groups were mainly related to a decrease in disease events (progression, second relapse, disease-related deaths; HR 0·56, 0·34–0·92, p=0·007) rather than an increase in adverse treatment effects (treatment death, second malignancy; HR 0·52, 0·24–1·11, p=0·11). Interpretation As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation. Funding Cancer Research UK, Leukaemia and Lymphoma Research, Cancer Council NSW, and Sporting Chance Cancer Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402922 · Cited by 563
Nachman, J. B., Sather, H. N., Sensel, M. G., Trigg, M. E., Cherlow, J. M., Lukens, J. N., Wolff, L., Uckun, F. M., & Gaynon, P. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382304 · Cited by 445
Seibel, N. L., Steinherz, P. G., Sather, H. N., Nachman, J. B., DeLaat, C., Ettinger, L. J., Freyer, D. R., Mattano, L. A., Hastings, C. A., Rubin, C. M., et al. (2008) · Blood · doi:10.1182/blood-2007-02-070342 · Cited by 312
Tallen, G., Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky, A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1983 · Cited by 308
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
Gibson, B. E. S., Wheatley, K., Hann, I. M., Stevens, R. F., Webb, D., Hills, R. K., De Graaf, S. S. N., Harrison, C. J., & for the United Kingdom Childhood Leukaemia Working Party, A. T. D. C. O. G. (2005) · Leukemia · doi:10.1038/sj.leu.2403924 · Cited by 303
Ko, R. H., Ji, L., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N. L., Twist, C. J., Eckroth, E., Sposto, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2950 · Cited by 281
Surrogate Endpoints And FDA’s Accelerated Approval Process
Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 249
Cited by
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614
Relapsed childhood acute lymphoblastic leukaemia
Bhojwani, D., & Pui, C.-H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70580-6 · Cited by 414
Borowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633685 · Cited by 362
Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J. D., Gruhn, B., Klingebiel, T., Parasole, R., Linderkamp, C., Flotho, C., Petit, A., et al. (2021) · JAMA · doi:10.1001/jama.2021.0987 · Cited by 348
Self-citationUnderstanding cancer and the anticancer activities of naphthoquinones – a review
Wellington, K. W. (2015) · RSC Advances · doi:10.1039/c4ra13547d · Cited by 316
Metadata
- Authors
- Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., Green, N., Révész, T., Darbyshire, P., Love, S., & Saha, V.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 376
- Issue
- 9757
- Pages
- 2009-2017
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2101272773
- Cited by
- 330
- References
- 17
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(10)62002-8
- The paper
- Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., Green, N., Révész, T., Darbyshire, P., Love, S., & Saha, V. (2010). Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(10)62002-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.